A carrier 131 I. Preparation and application of nanoparticles

By preparing a 131I nanoformula, using cyclodextrin and albumin to encapsulate radioactive iodine, and enhancing endocytosis through the SPARC-HSA-gp60-Caveolae pathway, the treatment problem of iodine-refractory thyroid cancer was solved and new treatment was achieved The method improves the therapeutic effect.

CN116139300BActive Publication Date: 2024-11-01SHENZHEN YUANSHI BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202310172017.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-21
Publication Date
2024-11-01
Estimated Expiration
2043-02-21

AI Technical Summary

Technical Problem

Iodine-refractory differentiated thyroid cancer (RAIR-DTC) is due to downregulation of NIS expression and abnormal membrane localization, which leads to radioactive iodine inability to enter cancer cells. The existing treatment methods are not effective and lack effective iodine delivery routes.

Method used

By screening suitable intermediate carriers, a 131 I nanoformula was prepared, and radioiodine was wrapped with 2-hydroxypropyl-β-cyclodextrin and albumin, and combined with the SPARC-HSA-gp60-Caveolae pathway, enhancing the endocytosis of tumor cells. A new delivery system for radioactive iodine.

Benefits of technology

A new pathway for 131 iodine treatment has been created, allowing RAIR-DTC to continue to receive 131 iodine treatment to provide new breakthroughs and improve the effectiveness of treating refractory thyroid cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116139300B_ABST
    Figure CN116139300B_ABST
Patent Text Reader

Abstract

The present invention discloses 131 Preparation and application of I nano-preparation, first prepare 2-HP-β-CD-NaI3 inclusion compound, then combine the inclusion compound with albumin to prepare HSA-2-HP-β-CD-NaI3 nano-preparation. The present invention loads radioactive iodine nuclides on a cyclodextrin carrier and uses albumin to wrap it to prepare an iodine-containing nano-preparation with high biocompatibility and no immune response. At the same time, by changing the adsorption amount of 131I nuclides on the carrier, the radiation dose can be controlled, making it a new method for treating thyroid cancer, with simple steps, stable product quality and good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of preparation of iodine-containing nanoparticles, and particularly relates to a nanoparticle containing iodine. 131 I. Preparation and application of nanoformulations. Background Art

[0002] As the incidence of thyroid cancer continues to rise, iodine-refractory differentiated thyroid cancer has become a difficult problem in clinical diagnosis and treatment. RAIR-DTC (iodine-refractory differentiated thyroid cancer) is mainly caused by down-regulation of NIS expression and abnormal membrane localization, which leads to impaired iodine uptake in cells, making it impossible for radioactive iodine to enter cancer cells, resulting in 131 I treatment is ineffective. The indications, efficacy and evaluation methods of current targeted drug therapy, local therapy and systemic chemotherapy are still controversial. Therefore, RAIR-DTC has become a hot spot and difficulty in the clinical treatment of thyroid cancer. Compared with other treatments, radioactive iodine itself has good physical properties, low price and good therapeutic effect. If another iodine delivery carrier can be found to replace the NIS transport method, and the radioactive iodine delivery carrier is distributed in the tumor tissue through intravenous systemic administration or local intratumoral injection, the radioactive iodine will eventually be delivered to the RAIR-DTC cells through the interaction between the carrier and the cells, then it will have far-reaching significance for the treatment of RAIR-DTC patients. Studies have found that most solid tumor tissue cells secrete high levels of cysteine-rich acidic secretory protein (secreted protein In acIdIc and rIch In cysteIne, SPARC), and SPARC can specifically bind to HSA. HSA molecules contain abundant binding sites and can be physically cross-linked with a variety of small molecule drugs through hydrophobic interactions, thereby helping to deliver anticancer drugs into tumor tissues. Therefore, SPARC can concentrate drugs bound to HSA in the interstitial tissue of tumor cells. Therefore, HSA nanoformulations have become promising drug preparations for killing iodine-refractory thyroid cancer cells.

[0003] Iodine does not bind to albumin when transported in the body. Iodine flows through the body in the form of inorganic iodine ions in the blood, is distributed in the extracellular fluid, and is finally enriched by thyroid cells. When preparing albumin nanoparticles, it is not possible to directly form iodine-containing albumin nanoparticles by physically embedding iodine ions.

[0004] Therefore, it is necessary to provide an intermediate carrier material that is loaded with iodine and then coated with albumin to prepare a nanoformulation with good biocompatibility suitable for imaging and treatment. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a carrier by screening a suitable intermediate carrier. 131 I. Preparation and application of nanoformulations.

[0006] In order to achieve the above object, one of the technical solutions adopted by the present invention is: a carrier 131 The preparation of nanometer preparations comprises the following steps:

[0007] S1, dissolving 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) in distilled water;

[0008] S2, weigh I2 and add CI Na 131 I, then add distilled water to dissolve to generate Na 131 I3 solution;

[0009] S3, the solutions prepared in S1 and S2 are stirred and mixed at low temperature to obtain 131 The 1-cyclodextrin inclusion compound solution (hereinafter referred to as "inclusion compound") is sealed and stored at low temperature for later use;

[0010] S4, human albumin lysis;

[0011] S5, taking a certain amount of the inclusion compound obtained in S3 and adding it to the S4 solution, stirring it thoroughly at room temperature to obtain a mixed solution;

[0012] S6, adding anhydrous ethanol dropwise to the mixed solution until the solution becomes turbid and then stopping the addition of anhydrous ethanol;

[0013] S7, adding 7% glutaraldehyde solution and continuing to stir in a sealed manner for a certain period of time to perform chemical cross-linking and curing;

[0014] S8, the cured 131 The I-cyclodextrin-albumin nanoformulation is dialyzed with distilled water to obtain a nanoformulation free of organic solvent and cross-linking agent.

[0015] Preferably, the mixing in S3 is carried out under stirring at 0°C.

[0016] Preferably, the molar ratio of the inclusion complex to the added amount of albumin is 5:1.

[0017] The second technical solution adopted by the present invention is: a 131 The application of nano-preparation in the preparation of tumor diagnostic reagents is achieved through the following technical solutions: 131 I. Application of nanoformulations in the preparation of tumor imaging agents.

[0018] The third technical solution adopted by the present invention is: 131 The application of nano preparations in the preparation of anti-tumor drugs is achieved through the following technical solutions: 131 Application of nanoformulations in the preparation of drugs for the treatment of refractory thyroid cancer.

[0019] Beneficial effects of the present invention:

[0020] The present invention adopts the above technical scheme, and prepares an iodine-containing nano preparation by loading the radioactive iodine nuclide on a cyclodextrin carrier and wrapping it with albumin, so as to make it a new drug delivery system for thyroid cancer cells. The characteristics of the albumin nano-nano carrier are utilized to enhance the endocytosis of tumor cells through the secreted protein acidic and rich in cysteine ​​(SPARC) and glycoprotein 60 (Gp60) pathways, solve the problem of "iodine pump" failure, and use the SPARC-HSA-gp60-Caveolae pathway to allow radioactive iodine to enter the cell through a new endocytic pathway, and the enriched radioactive iodine decays to emit a certain cumulative dose of beta rays to achieve the purpose of treatment. A new 131 iodine treatment pathway for thyroid cancer is created, making it possible for RAIR-DTC to continue 131 iodine treatment, and the nano preparation is expected to provide a new breakthrough in the treatment of iodine-refractory differentiated thyroid cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art and the beneficial effects of the present invention, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other structures can be obtained based on the structures shown in these drawings without paying creative work.

[0022] Figure 1 DLS measurement for the present invention 131 Particle size distribution curve of I-cyclodextrin-albumin nanoformulation.

[0023] Figure 2 For the present invention 131 I- Transmission electron microscopy image of cyclodextrin-albumin nanoformulation (inclusion complex: HSA = 0:1).

[0024] Figure 3 For the present invention 131 I- Transmission electron microscopy image of cyclodextrin-albumin nanoformulation (inclusion complex: HSA = 5:1)

[0025] Figure 4 It is the particle size frequency distribution histogram of the present invention (inclusion compound: HSA=0:1).

[0026] Figure 5 It is the particle size frequency distribution histogram (inclusion complex: HSA=5:1).

[0027] Figure 6 is the standard curve,

[0028] Figure 7 For the present invention 131 I-cyclodextrin-albumin nanoformulation I3 - UV-visible characteristic absorption peak. DETAILED DESCRIPTION

[0029] The main experimental materials and reagents in the specific embodiments of the present invention are (Table 1):

[0030] Table 1

[0031]

[0032] Stable iodine (iodine-127) has the same chemical properties as radioactive iodine-131. The stable iodine used in the experiment of the present invention is easier to obtain and will not affect the research results. In addition, the experimenters do not need to take radiation protection during the experiment.

[0033] Embodiment 1:

[0034] A carrier 131 The preparation of the nano-preparation is firstly carried out to prepare the 2-HP-β-CD-NaI3 inclusion compound, which specifically comprises the following steps:

[0035] (1) Accurately weigh 2-HP-β-CD 12.0000 g (7.78 × 10 -3 mol) was placed in a small beaker and 5 ml of double distilled water was added to completely dissolve it;

[0036] (2) Precision weighing I21.0000g (3.9×10 -3 mol), NaI 0.5850 g (3.9 × 10 -3 mol), placed in another small beaker, added 10 ml of double distilled water, stirred and dissolved with an electromagnetic stirrer, reacted to generate a NaI3 solution, and then poured into the beaker of the above 2-HP-β-CD solution, the beaker of the mixed solution was placed in an ice water bath and stirred with an electromagnetic stirrer for 8 hours until the mixture was 1 mol. 3- be fully contained;

[0037] (3) The mixture was transferred to an eggplant-shaped bottle and connected to a rotary evaporator. After the solvent was evaporated, a 2-HP-β-CD-NaI3 inclusion complex solid was obtained. The product attached to the bottle wall was scraped off with a stainless steel spatula, placed in an EP tube, sealed, and stored in a refrigerator at 4°C.

[0038] Then, the preparation of HSA-2-HP-β-CD-NaI3 nanoformulation:

[0039] The desolvation method is a commonly used method for preparing HAS nanoparticles. The desolvation method is to remove the hydration film of albumin with anhydrous ethanol under stirring to precipitate the albumin, and then introduce a cross-linking agent to react with the albumin to form spherical albumin nanoparticles, which are then purified to remove the residual cross-linking agent and organic solvent.

[0040] Nanoformulations were prepared with different molar ratios of 2-HP-β-CD-NaI3 and HSA, namely 0:1 (inclusion complex: albumin = 0), 0.5:1 (inclusion complex: albumin = 0.5), 1:1 (inclusion complex: albumin = 1), 2:1 (inclusion complex: albumin = 2), 5:1 (inclusion complex: albumin = 5) and 10:1 (inclusion complex: albumin = 10).

[0041] The specific steps include:

[0042] (1) Accurately weigh 2-HP-β-CD-NaI3 inclusion compound and place it in a small beaker. Add 10 ml of double distilled water to completely dissolve it.

[0043] (2) accurately weighing human serum albumin (HSA) and dissolving it in the inclusion compound solution;

[0044] (3) stirring the mixture at room temperature and 1500 rpm using a magnetic stirrer;

[0045] (4) At the same time, draw 20 ml of anhydrous ethanol with a syringe, install it on a syringe pump, and add it dropwise to the above mixed solution at a flow rate of 2 ml / min while stirring. Stop the injection as soon as the mixed solution becomes turbid;

[0046] (5) Add 50 μL of 0.025 kg / L glutaraldehyde solution and place the mixed solution beaker in a 37°C constant temperature water bath for 3 hours to perform chemical crosslinking and curing;

[0047] (6) The solidified HSA-2-HP-β-CD-NaI3 nanoparticle dispersion is dialyzed with distilled water, poured into a common dialysis bag (molecular cutoff of 8000-14000Da), clamped and dialyzed for 24 hours, and the distilled water is continuously replaced during the process to obtain a nanocolloid free of organic solvent and 2-HP-β-CD inclusion complex;

[0048] (7) The colloid was transferred to an evaporating dish, covered with plastic wrap, and pierced with appropriate small holes. The colloid was placed in a -20°C refrigerator overnight to condense, and then placed in a freeze dryer for 36-48 hours. After freeze drying, HSA-2-HP-β-CD-NaI3 solid was obtained. The product attached to the inner wall was scraped off with a stainless steel spatula, placed in an EP tube, sealed, and stored in a 4°C refrigerator.

[0049] Embodiment 2, a kind of above131 Application of I nanoformulations in the preparation of tumor imaging agents, preparation of iodine-loaded nanoformulations labeled with fluoresceIn 5-IsothIocyanate (FITC), specifically comprising the following steps: (1) Accurately weigh 0.1000g of HSA-2-HP-β-CD-NaI3 nanoformulation dry product (inclusion complex: albumin = 5), pour into a conical flask, then add pH = 9.8 sodium bicarbonate buffer (freshly prepared) containing 0.1mg / ml FITC, fully shake and disperse, place in a 4°C refrigerator, shake on a shaker overnight. Note that after adding fluorescein, cover the conical flask with aluminum foil to avoid light;

[0050] (2) The mixed solution was transferred to a centrifuge tube, placed in an Eppendorf 5415 high-speed refrigerated centrifuge and centrifuged at 5000 g for 3-4 times, each centrifugation taking 2 hours, until the solvent was colorless;

[0051] (3) After centrifugation, pour the marker solution in the centrifuge tube into a plastic tube wrapped with aluminum foil and store it in a refrigerator at 4°C.

[0052] Embodiment 3, a kind of above 131 Application of nanoformulations in the preparation of drugs for the treatment of anaplastic thyroid cancer.

[0053] The verification was carried out through the preparation and culture of SLC5A5 gene knockout B-CPAP cells and the endocytosis experiment of the nanoformulation.

[0054] Step 1. Preparation of SLC5A5 knockout B-CPAP cells

[0055] SLC5A5 gene retrieval and gRNA design, selection of human SLC5A5 gene Exon 2-8 as knockout site based on transcript and protein encoding information, design and synthesis of primers, and construction of knockout vector. Thyroid cancer cell culture, thyroid papillary carcinoma B-CPAP cell line was incubated in 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Cells were cultured under the environmental conditions of gas phase: 95% air, 5% carbon dioxide, temperature: 37 degrees Celsius, and incubator humidity of 70%-80%. The culture medium was replaced every 1-2 days, and the cells were subcultured when the cell density was >80%. Transfected cell drug screening to obtain stable mixed clone cells.

[0056] Genotyping of knockout cell lines

[0057] DNA was extracted from untransfected cells (i.e., wild-type cells) and mixed cloned cells (i.e., knockout cells) and PCR amplification was performed using designed and synthesized primers. The amplification system was: 5 μL of PremIx Taq, 0.5 μL of each forward and reverse primer, 2 μL of each of the above DNA templates, and 5 μL of distilled water. Amplification conditions were: pre-denaturation at 95°C for 3 minutes; denaturation at 95°C for 20 seconds, annealing at 56°C for 20 seconds, extension at 72°C for 40 seconds, for a total of 30 cycles; extension at 72°C for 5 minutes, and storage at 4°C.

[0058] Step 2, endocytosis experiment of nanoformulation

[0059] (1) Preparation of slides: Soak the cleaned coverslip in anhydrous ethanol for 6 hours, wash it again with double distilled water, place it in a stainless steel container and sterilize it in a pressure steam sterilizer, take it out and dry it for later use;

[0060] (2) Cell culture: Under sterile conditions, drop the above cell culture medium into the culture dish, spread the sterilized cover slip in the center of the culture dish, and then digest the B-CPAP cells with trypsin to make suspension cells. 4 The cells were inoculated into a culture dish at a cell density of / ml for culture. After 24 hours, the cells adhered to the wall and grew well, and the cells climbed the plate completely.

[0061] (3) Addition of nano-drugs: The FITC-labeled iodine-loaded nano-preparation solution was ultrasonically dispersed for 10 minutes, filtered with a 0.45 μm microporous filter membrane to remove bacteria, and added to the cell culture medium to make a drug-containing culture medium and dispersed into 1.0×10 13 nanoparticles / mL, the culture dish supernatant was removed, the culture medium containing labeled nanoparticles was added and incubated in an incubator for 8 h;

[0062] (4) Cell fixation: remove the supernatant, wash three times with phosphate buffered saline (PBS) to remove un-internalized nanoparticles, add 4% paraformaldehyde solution to fix at room temperature for 15 min, wash three times with PBS, and then gradually dehydrate with 30%, 50%, 70%, 80%, 90% and 100% ethanol solutions, remove the slide with tweezers, and dry the surface liquid;

[0063] (5) Localization of Nanoparticles: The dried slides were observed using a Carl Zeiss AxIo Vert.A1 inverted fluorescence microscope to visualize and photograph the internalization of FITC-labeled iodine-loaded nanoparticles.

[0064] Fluorescence imaging technology was used to study whether HSA-2-HP-β-CD-NaI3 nanoparticles can be internalized into cells when incubated with thyroid papillary cancer cells B-CPAP in vitro. After FITC-labeled HSA-2-HP-β-CD-NaI3 nanoparticles were incubated with thyroid papillary cancer B-CPAP cells at a concentration of (inclusion complex: albumin = 5) 1.0×1013 nanoparticles / mL for 8 hours, they were observed by inverted fluorescence microscope. Since FITC excitation will emit green fluorescence, green fluorescence can be clearly seen in the cells, indicating that FITC-labeled HSA-2-HP-β-CD-NaI3 nanoparticles can be internalized by thyroid papillary cancer cells B-CPAP.

[0065] Experimental Example: Characterization of the HSA-2-HP-β-CD-NaI3 nanoformulation prepared in Example 1

[0066] 1) Dynamic light scattering (DLS) and Zeta potential

[0067] A small amount of the prepared lyophilized nanoformulation was reconstituted in 5 ml of double distilled water, ultrasonically dispersed for 10 minutes, filtered with a 0.45 um microporous filter membrane to prepare a sample, and then the size, potential and polydispersity index of the nanoformulation sample were measured using a dynamic light scattering particle size analyzer and a Zeta potential analyzer, and the measurement was repeated 3 times. The results are shown in Table 2.

[0068] Table 2 Hydrodynamic size, polydispersity index and zeta potential of nanoformulations

[0069]

[0070] The hydrodynamic size, polydispersity index and Zeta potential value of the synthesized HSA-2-HP-β-CD-NaI3 nanoformulation were studied by dynamic light scattering and Zeta potential. Table 1 summarizes the partial particle size, PDI and Zeta potential data of each group of albumin-encapsulated iodine-loaded 2-hydroxypropyl-β-cyclodextrin nanoformulations. It can be seen from the table that the particle size of the group with a molar ratio of inclusion complex to HSA of 5:1 is the smallest, and the particle size of the group with a molar ratio of 0.5:1 is the largest. The PDI of the 10:1 group is the smallest and the particle size distribution is the narrowest; the PDI of the 0:1 group is the largest and the particle size distribution range is wide. The Zeta potential of the 0:1 group shows that its potential is the lowest, and the potentials of the 10:1 group and the 5:1 group are both close to -30mV.

[0071] like Figure 1 As shown, the average hydrodynamic diameter of the nanoformulation inclusion complex: HSA=5:1 group was measured to be 131.3±3.5 nm, PDI 0.209, and the particles of the nanoformulation in this group had only one distribution peak, and the particle size distribution was concentrated.

[0072] 2) Transmission electron microscopy

[0073] Take 1 ml of the sample prepared above, the inclusion complex: albumin = 5:1 group, and the inclusion complex: albumin = 0:1 group, and drop them onto the horizontal copper mesh, let them stand for 2 minutes to allow the nanoparticles to settle on the mesh, then use filter paper to absorb the surface moisture, and air dry at room temperature. Then use a transmission electron microscope to observe the morphology of the nanoparticles, take pictures and measure the particle size distribution.

[0074] The morphology of the prepared HSA-2-HP-β-CD-NaI3 nanoformulation was characterized by transmission electron microscopy, see Figure 2 , Figure 3 .like Figure 2 As shown, the particles of the inclusion complex: HSA=0:1 group (i.e., pure albumin group) are irregularly circular in two-dimensional plane, the particles adhere and aggregate into clusters, and the particle size is mostly greater than 200 nm. Figure 3 The transmission electron microscope image shown in the figure clearly shows that the single dispersed nanoparticles of the inclusion complex HSA = 5:1 group are round or elliptical in shape on a two-dimensional plane, without obvious aggregation. The particle size data of 100 nanoparticles were obtained by randomly measuring them, and a particle size frequency distribution histogram was drawn, as shown in the figure below. Figure 4 The particle size range of the inclusion complex: HSA = 0:1 group is 103-558nm, and the average particle size is calculated to be 302.4nm, and the particle size distribution is uneven. Figure 5 As shown, the particle size range of the inclusion complex:HSA=5:1 group is 52-137nm, the average particle size is calculated to be 86.8nm, and the particle size distribution roughly conforms to the normal distribution.

[0075] 3) UV-Visible Photometer Detection

[0076] After NaI3 is configured into a certain concentration gradient, the absorbance value of the solution is measured at 350nm using a UV-visible photometer, and the concentration data between 0.2-0.8 is taken, and then a standard curve is made with the concentration as the x-axis and the absorbance as the y-axis. At the same time, the absorbance of the HSA-2-HP-β-CD-NaI3 nanoformulation is measured at this wavelength, and substituted into the regression equation of the standard curve to obtain I 3- The concentration of the albumin nanoformulation can be obtained.

[0077] (1) Prepare NaI3 solutions with concentrations of 1.5×10-4mol / L, 2.5×10-4mol / L, 5.5×10-4mol / L, 8.5×10-4mol / L, and 1.5×10-3mol / L, and use double distilled water as a comparison. The UV-visible spectrum is measured using a VarIanCary-EclIpse 500 spectrophotometer. The maximum absorption wavelength is found to be 350nm, and the absorbance value at this wavelength is taken to draw a standard curve;

[0078] (2) Accurately weigh 0.1000 g of HSA-2-HP-β-CD-NaI3 nanoparticle dry product, dissolve it in 10 ml of double distilled water, transfer 1 ml of the solution to the absorption cell with a pipette, and measure the absorbance value of the obtained HSA-2-HP-β-CD-NaI3 nanoparticles with a UV-visible spectrometer. Repeat the measurement three times. Calculate the iodine content in the HSA-2-HP-β-CD-NaI3 nanoparticle using the above standard curve.

[0079] The drug loading (DL) and encapsulation efficiency (EE) were calculated as follows:

[0080] DL% is the drug loading rate (%). The mass of drug in nanoparticles (weight of drug in nanoparticles) is the mass of encapsulated drug, and the mass of nanoparticles (weight of nanoparticles) is the total mass of the corresponding drug-encapsulated nanoparticles.

[0081] EE% is the efficiency of encapsulation (%), the mass of drug in nanoparticles (weght of drug In nanoparticles) and the mass of initial drug (weght of In Ital drug) represent the total mass of powder obtained after freeze drying and the drug initially fed in the nanoparticle preparation step.

[0082] See also Figure 6 After configuring NaI3 into a certain concentration gradient, use a UV-visible photometer to measure the absorbance of the solution at 350nm, take the concentration data between 0.2-0.8, and then use the concentration as the x-axis and the absorbance as the y-axis to obtain the standard curve: Y=1094X-0.1358.

[0083] The absorbance value of the nanoformulation can be measured to obtain the iodine concentration according to the standard curve, and then the drug loading rate and encapsulation rate of the nanoformulation can be calculated based on this. As shown in Table 3, the drug loading rate of the inclusion complex: HSA = 5:1 group is the highest; the encapsulation rate of the inclusion complex: HSA = 0.5:1 group is the highest.

[0084] Table 3 Drug loading rate and encapsulation efficiency of nanoformulations

[0085]

[0086] 5) Stability test of nanoformulations

[0087] (1) The iodine-loaded nanoformulation (inclusion complex: albumin = 5:1) was dispersed in sterile acetic acid (pH = 5.0) and phosphate buffered saline (PBS) (pH = 5.8, 6.8) and physiological saline (pH = 7.4), and stored at 4 degrees Celsius for one month to investigate the stability of the iodine-loaded nanoformulation in solutions with different pH values. 1 ml of the stored nanoformulation dispersion was transferred to a UV-visible spectrophotometer with a pipette to measure the absorbance, see Figure 7 .

[0088] (2) The HAS, 2-HP-β-CD, I2 and NaI raw materials were physically mixed and the HSA-2-HP-β-CD-NaI3 freeze-dried preparation was placed at room temperature for 48 hours, and the differences in the two groups of EP storage tubes were compared. The HAS, 2-HP-β-CD, I2 and NaI raw materials were physically mixed and the HSA-2-HP-β-CD-NaI3 freeze-dried preparation was placed at room temperature for 48 hours. By comparing the two figures, significant differences can be observed. After simple physical mixing, iodine sublimates to cause the tube wall to appear brown-yellow, while the inclusion complex formed by 2-HP-β-CD-NaI3 does not sublimate the tube wall after placement to cause the tube wall to show color, indicating that the nanoformulation dry powder can exist stably at room temperature and the iodine is tightly wrapped by cyclodextrin and albumin.

[0089] The HSA-2-HP-β-CD-NaI3 nanoformulation (inclusion complex and HSA molar ratio of 5:1) prepared by the present invention has an average hydrodynamic diameter of about 131.3 nm, a narrow particle size distribution range, good stability, and a high drug loading rate, so the preparation meets the prerequisite requirements for thyroid cancer treatment. In the fluorescence photography results of the endocytosis experiment of nanoparticles by thyroid papillary cancer cells, green fluorescence can be clearly seen in the cells, and it can be seen that the FITC-labeled HSA-2-HP-β-CD-NaI3 nanoformulation particles can enter the thyroid papillary cancer cells. In future studies, it provides a basis for further in-depth effectiveness studies such as in vitro cytotoxicity and in vivo anti-tumor effects of HSA nanoformulations loaded with iodine-131.

[0090] The above are only preferred embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.

Claims

1. A carrier 131 A method for preparing a nano preparation, characterized in that: The following steps are involved: S1, dissolving 2-hydroxypropyl-β-cyclodextrin in distilled water; S2, weigh I2 and add Na 131 I solution, and then add distilled water to dissolve to generate Na 131 I3 solution; S3, the solutions prepared in S1 and S2 are stirred and mixed at low temperature to obtain 131 The I-cyclodextrin inclusion compound solution is sealed and stored at low temperature for later use; S4, human albumin lysis; S5, taking a certain amount of the inclusion compound obtained in S3 and adding it to the S4 solution, stirring it thoroughly at room temperature to obtain a mixed solution; S6, adding anhydrous ethanol dropwise to the mixed solution until the solution becomes turbid and then stopping the addition of anhydrous ethanol; S7, adding glutaraldehyde solution and continuing to stir in a sealed manner for a certain period of time to perform chemical cross-linking and curing; S8, the cured 131 The I-cyclodextrin-albumin nanoformulation is dialyzed with distilled water to obtain a nanoformulation free of organic solvent and cross-linking agent.

2. The carrier according to claim 1 131 A method for preparing a nano preparation, characterized in that: The S3 was mixed with stirring at 0°C.

3. The carrier according to claim 1 131 A method for preparing a nano preparation, characterized in that: The molar ratio of the inclusion complex to the added albumin is 5:1.

Citation Information

Patent Citations

  • Application of human blood albumin in preparation of radioactive iodine-labeled hypericin medicine preparation

    CN113143854A

  • < 131 > I-HSA-ICG nanoparticles as well as preparation method and application thereof

    CN114848854A

  • Pharmaceutical compositions containing polyrotaxanes

    WO2019191049A1